Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study - Segal, B M; Constantinescu, C S; Raychaudhuri, A (Lancet Neurol, 2008)
et al.